Mounjaro vs Ozempic: A Complete Head-to-Head Comparison

Introduction

Choosing between Mounjaro and Ozempic isn't straightforward. Both medications have transformed obesity treatment, but they work differently and produce different results.

The evidence now strongly favors one over the other for weight loss. In the first head-to-head trial comparing these drugs in people without diabetes, the difference was striking: tirzepatide achieved 20.2% weight loss versus 13.7% with semaglutide.

Evidence: "The least-squares mean percent change in weight at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide." — Aronne LJ, et al. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394

But weight loss isn't the only factor. Side effects, cost, availability, and your individual health profile all matter. This guide breaks down what the science actually shows.

What Are These Medications?

Ozempic (Semaglutide)

Semaglutide is a GLP-1 receptor agonist. It mimics a naturally occurring hormone that regulates appetite, blood sugar, and digestion. Originally developed for type 2 diabetes, it's now approved for weight management under the brand name Wegovy.

Key characteristics:

Single hormone action (GLP-1 only)
Weekly injection
Approved for diabetes (Ozempic) and obesity (Wegovy)
Doses range from 0.25 mg to 2.4 mg

Mounjaro (Tirzepatide)

Tirzepatide is newer and works differently. It's a dual agonist, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism appears to produce more potent weight loss effects.

Key characteristics:

Dual hormone action (GLP-1 + GIP)
Weekly injection
Approved for diabetes (Mounjaro) and obesity (Zepbound)
Doses range from 2.5 mg to 15 mg

Head-to-Head Clinical Evidence

SURMOUNT-5: The Definitive Comparison

Published in the New England Journal of Medicine in May 2025, SURMOUNT-5 was the first randomized trial to directly compare tirzepatide and semaglutide in adults with obesity but without diabetes.

The results were clear:

Outcome	Tirzepatide	Semaglutide	Difference
Mean weight loss	20.2%	13.7%	6.5 percentage points
Waist circumference reduction	18.4 cm	13.0 cm	5.4 cm
Achieved ≥10% weight loss	81.4%	60.5%	+20.9 percentage points
Achieved ≥15% weight loss	70.6%	42.2%	+28.4 percentage points
Achieved ≥20% weight loss	51.3%	22.8%	+28.5 percentage points
Achieved ≥25% weight loss	34.1%	16.1%	+18.0 percentage points

Evidence: "Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%." — Aronne LJ, et al. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394

SURPASS-2: Earlier Evidence in Type 2 Diabetes

Before SURMOUNT-5, the SURPASS-2 trial compared these medications in patients with type 2 diabetes. Tirzepatide demonstrated superior weight loss here as well.

At 40 weeks:

Tirzepatide 5 mg: 1.9 kg more weight loss than semaglutide
Tirzepatide 10 mg: 3.6 kg more weight loss than semaglutide
Tirzepatide 15 mg: 5.5 kg more weight loss than semaglutide

Evidence: "Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, −1.9 kg, −3.6 kg, and −5.5 kg, respectively; P<0.001 for all comparisons)." — Frías JP, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107519

Meta-Analysis Confirmation

A 2025 meta-analysis pooling results from randomized trials and real-world studies confirmed tirzepatide's superior weight loss efficacy.

The pooled analysis showed:

Mean difference in weight loss: 4.23% greater with tirzepatide (95% CI: 3.22-5.25)
Dose-dependent effect: >10 mg doses showed 6.50% greater weight loss
Duration-dependent effect: >6 months showed 5.00% greater weight loss

Evidence: "The pooled analysis provides evidence that tirzepatide is better than semaglutide in reducing body weight, regardless of study design." — Malecki et al. J Clin Med Res. 2025. PMC

Real-World Effectiveness

Clinical trials don't always reflect everyday experience. A large real-world study of 18,386 propensity-score matched patients found that while both medications produce significant weight loss, tirzepatide maintained its advantage.

Key findings at 12 months:

Most patients on both drugs achieved ≥5% weight loss
Tirzepatide showed consistently higher rates of achieving 10%, 15%, and 20% weight loss thresholds
Discontinuation rates were substantial for both medications

Evidence: "Although most adults with overweight or obesity experienced 5% or greater weight loss with treatment, the benefit was greater with tirzepatide." — Wadden TA, et al. JAMA Intern Med. 2024. DOI: 10.1001/jamainternmed.2024.2525

Side Effects Comparison

Both medications share similar side effect profiles, primarily gastrointestinal. Most are mild to moderate and occur during dose escalation.

Common Side Effects (SURMOUNT-5 data)

Side Effect	Tirzepatide	Semaglutide
Nausea	35%	33%
Diarrhea	21%	17%
Vomiting	17%	14%
Constipation	17%	22%
Dyspepsia	13%	9%
Abdominal pain	12%	10%

Discontinuation Due to Side Effects

In SURMOUNT-5:

Tirzepatide: 6.1% discontinued due to adverse events
Semaglutide: 4.0% discontinued due to adverse events

The higher discontinuation rate with tirzepatide likely reflects its more aggressive dosing escalation and greater efficacy—some patients experience more intense side effects as they reach higher doses.

Serious Adverse Events

Both medications have rare but serious risks:

Pancreatitis: Rare but requires immediate medical attention if severe abdominal pain occurs
Gallbladder disease: Increased risk, particularly with rapid weight loss
Thyroid C-cell tumors: Black box warning based on rodent studies; human risk unclear
Hypoglycemia: More common when combined with insulin or sulfonylureas

Dosing and Administration

Ozempic/Wegovy Dosing

Ozempic (diabetes):

Starting: 0.25 mg weekly for 4 weeks
Escalation: 0.5 mg → 1 mg → 2 mg as needed
Maximum: 2 mg weekly

Wegovy (obesity):

Starting: 0.25 mg weekly for 4 weeks
Escalation: 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Maximum: 2.4 mg weekly

Mounjaro/Zepbound Dosing

Mounjaro (diabetes) and Zepbound (obesity):

Starting: 2.5 mg weekly for 4 weeks
Escalation: 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Maximum: 15 mg weekly

Key Differences in Dosing

Tirzepatide offers more granular dose escalation steps. This can be advantageous for patients who experience side effects at higher doses—you can titrate more slowly. However, reaching the maximum effective dose takes longer.

Cost and Insurance Coverage

List Prices (US, monthly)

Medication	List Price	Notes
Ozempic	~$935	Often covered for diabetes
Wegovy	~$1,349	Prior authorization typically required
Mounjaro	~$1,023	Coverage varies by plan
Zepbound	~$1,060	Newer, coverage expanding

Insurance Considerations

Diabetes diagnosis: Generally easier to get coverage for Ozempic or Mounjaro
Obesity-only diagnosis: Wegovy and Zepbound may require BMI documentation and prior authorization
Medicare: Coverage for obesity medications is limited; diabetes indication improves access
Manufacturer savings programs: Both Eli Lilly and Novo Nordisk offer patient assistance programs

Who Should Choose Which?

Consider Tirzepatide (Mounjaro/Zepbound) If:

You want maximum possible weight loss
You've tried semaglutide with suboptimal results
You tolerate medications well and can manage dose escalation
Cost and access are comparable

Consider Semaglutide (Ozempic/Wegovy) If:

You prefer a medication with a longer track record
You experienced significant side effects with tirzepatide
Insurance coverage is substantially better
You have specific contraindications to dual agonists

Special Populations

Type 2 diabetes: Both medications improve glycemic control. Tirzepatide may offer superior HbA1c reduction based on SURPASS-2 data.

Cardiovascular disease: Semaglutide has more established cardiovascular outcome data (SELECT trial). Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing.

Gastrointestinal sensitivity: If you have a history of severe GI issues, semaglutide's gentler profile might be preferable, though individual responses vary.

The Bottom Line

The evidence is now clear: tirzepatide produces greater weight loss than semaglutide in head-to-head comparisons. The 6.5 percentage point difference in SURMOUNT-5 translates to meaningful additional weight loss—for a 100 kg person, that's an extra 6.5 kg (14.3 lbs) on average.

However, "better" depends on your priorities:

Maximum weight loss: Tirzepatide wins
Side effect tolerance: Individual; semaglutide may be gentler for some
Cost/access: Varies by insurance; semaglutide may have better coverage
Cardiovascular data: Semaglutide has more long-term outcome data

Neither medication is a magic solution. Both require ongoing use, lifestyle modification, and medical supervision. The weight returns if you stop—the underlying biology driving obesity remains.

Discuss with your healthcare provider which option aligns with your health goals, medical history, and practical constraints.

References

Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for Weight Loss in Adults with Obesity but Not Diabetes. N Engl J Med. 2025;393:26-36. DOI: 10.1056/NEJMoa2416394
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515. DOI: 10.1056/NEJMoa2107519
Malecki et al. Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis. J Clin Med Res. 2025. PMC
Wadden TA, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. DOI: 10.1001/jamainternmed.2024.2525
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly Press Release. December 4, 2024. Link

Last updated: February 27, 2026
Medical review: Dr. James Chen, MD, PhD, FACE

Important Notice: This content is for informational and educational purposes only. It does not replace medical consultation, diagnosis, or treatment. Medications mentioned should only be used under medical prescription and supervision. Side effects and contraindications exist. Consult a qualified healthcare provider.